Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30134590,flux,"Cumulative net PDV flux of B12 for SC, TB12, and CC were 2.9, 4.4, and 8.3 µg 23 h post-meal, corresponding to a bioavailability of 11.6%, 17.5%, and 33.0%, respectively.",Bioavailability of Vitamin B12 from Dairy Products Using a Pig Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30134590/),μg,2.9,16,DB00115,Cyanocobalamin
,30134590,flux,"Cumulative net PDV flux of B12 for SC, TB12, and CC were 2.9, 4.4, and 8.3 µg 23 h post-meal, corresponding to a bioavailability of 11.6%, 17.5%, and 33.0%, respectively.",Bioavailability of Vitamin B12 from Dairy Products Using a Pig Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30134590/),μg,4.4,17,DB00115,Cyanocobalamin
,30134590,flux,"Cumulative net PDV flux of B12 for SC, TB12, and CC were 2.9, 4.4, and 8.3 µg 23 h post-meal, corresponding to a bioavailability of 11.6%, 17.5%, and 33.0%, respectively.",Bioavailability of Vitamin B12 from Dairy Products Using a Pig Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30134590/),μg,8.3,18,DB00115,Cyanocobalamin
,30134590,bioavailability,"Cumulative net PDV flux of B12 for SC, TB12, and CC were 2.9, 4.4, and 8.3 µg 23 h post-meal, corresponding to a bioavailability of 11.6%, 17.5%, and 33.0%, respectively.",Bioavailability of Vitamin B12 from Dairy Products Using a Pig Model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30134590/),%,11.6,19,DB00115,Cyanocobalamin
,30134590,bioavailability,"Cumulative net PDV flux of B12 for SC, TB12, and CC were 2.9, 4.4, and 8.3 µg 23 h post-meal, corresponding to a bioavailability of 11.6%, 17.5%, and 33.0%, respectively.",Bioavailability of Vitamin B12 from Dairy Products Using a Pig Model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30134590/),%,17.5,20,DB00115,Cyanocobalamin
,30134590,bioavailability,"Cumulative net PDV flux of B12 for SC, TB12, and CC were 2.9, 4.4, and 8.3 µg 23 h post-meal, corresponding to a bioavailability of 11.6%, 17.5%, and 33.0%, respectively.",Bioavailability of Vitamin B12 from Dairy Products Using a Pig Model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30134590/),%,33.0,21,DB00115,Cyanocobalamin
,18257543,elimination,"Pharmacokinetic investigation of cis-ACCP in rats revealed distribution restricted into the extracellular fluid, which is the site of action for the antimetastatic activity and rapid elimination ( t 1/2 approximately 19 min) from blood.","Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18257543/),min,19,5578,DB00115,Cyanocobalamin
,18257543,t 1/2,Sustained and prolonged absorption ( t 1/2 approximately 126 min) occurred via paracellular mechanism along the small and large intestine with overall bioavailability of 0.3%.,"Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18257543/),min,126,5579,DB00115,Cyanocobalamin
,18257543,overall bioavailability,Sustained and prolonged absorption ( t 1/2 approximately 126 min) occurred via paracellular mechanism along the small and large intestine with overall bioavailability of 0.3%.,"Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18257543/),%,0.3,5580,DB00115,Cyanocobalamin
,32360544,orally bioavailable,It was also found that SNAC is orally bioavailable (almost 40%) when dosed to rats.,Evaluating the Pharmacokinetics and Systemic Effects of a Permeability Enhancer Sodium N-[8-(2-hydroxybenzoyl)amino] Caprylate in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32360544/),%,40,40144,DB00115,Cyanocobalamin
,2705197,time,The time taken to reach this threshold level in the control animals was 12 min.,Thiosulphate and hydroxocobalamin prophylaxis in progressive cyanide poisoning in guinea-pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2705197/),min,12,53604,DB00115,Cyanocobalamin
,2705197,plasma half-life,Additionally we found a plasma half-life of sodium thiosulphate in guinea-pigs of 26 min.,Thiosulphate and hydroxocobalamin prophylaxis in progressive cyanide poisoning in guinea-pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2705197/),min,26,53605,DB00115,Cyanocobalamin
,8012169,elimination half-life,"At 70 mg/kg, which is the recommended dose in acute cyanide poisoning, the elimination half-life was 7.36 +/- 0.79 h, the volume of distribution was 0.49 +/- 0.10 L/kg, and the total clearance 0.58 +/- 0.11 L/h.",Pharmacokinetics of hydroxocobalamin in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8012169/),h,7.36,59819,DB00115,Cyanocobalamin
,8012169,volume of distribution,"At 70 mg/kg, which is the recommended dose in acute cyanide poisoning, the elimination half-life was 7.36 +/- 0.79 h, the volume of distribution was 0.49 +/- 0.10 L/kg, and the total clearance 0.58 +/- 0.11 L/h.",Pharmacokinetics of hydroxocobalamin in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8012169/),[l] / [kg],0.49,59820,DB00115,Cyanocobalamin
,8012169,total clearance,"At 70 mg/kg, which is the recommended dose in acute cyanide poisoning, the elimination half-life was 7.36 +/- 0.79 h, the volume of distribution was 0.49 +/- 0.10 L/kg, and the total clearance 0.58 +/- 0.11 L/h.",Pharmacokinetics of hydroxocobalamin in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8012169/),[l] / [h],0.58,59821,DB00115,Cyanocobalamin
,25260366,lead-in time,Prior supplementation with folic acid and vitamin B12 is required to reduce pemetrexed therapy toxicity; the recommended lead-in time is at least 7 days.,A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260366/),,7,67200,DB00115,Cyanocobalamin
,25260366,response rate,The response rate to chemotherapy was 43%.,A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260366/),%,43,67201,DB00115,Cyanocobalamin
,25681732,bioavailability,"The bioavailability of VB12 was 0.6±0.2% when the chitosan-free VB12 solution was administered, while it increased to 10.5±3.3% when chitosan was dissolved in the VB12 solution at a concentration of 1%.","In vivo application of chitosan to improve bioavailability of cyanocobalamin, a form of vitamin B12, following intraintestinal administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25681732/),%,0.6,83049,DB00115,Cyanocobalamin
,25681732,bioavailability,"The bioavailability of VB12 was 0.6±0.2% when the chitosan-free VB12 solution was administered, while it increased to 10.5±3.3% when chitosan was dissolved in the VB12 solution at a concentration of 1%.","In vivo application of chitosan to improve bioavailability of cyanocobalamin, a form of vitamin B12, following intraintestinal administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25681732/),%,10.5,83050,DB00115,Cyanocobalamin
,25681732,bioavailability,It was also shown that the bioavailability of VB12 does not increase further when the degree of chitosan deacetylation is increased from 83 to 100% by substitutively employing the fully deacetylated chitosan.,"In vivo application of chitosan to improve bioavailability of cyanocobalamin, a form of vitamin B12, following intraintestinal administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25681732/),%,83,83051,DB00115,Cyanocobalamin
,25681732,bioavailability,It was also shown that the bioavailability of VB12 does not increase further when the degree of chitosan deacetylation is increased from 83 to 100% by substitutively employing the fully deacetylated chitosan.,"In vivo application of chitosan to improve bioavailability of cyanocobalamin, a form of vitamin B12, following intraintestinal administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25681732/),%,100,83052,DB00115,Cyanocobalamin
,22993315,peak serum concentrations,"Average peak serum concentrations of 2265, 5523 and 13,866 pg/mL were achieved following single-dose bolus intravenous administration of 10 mg/kg, 20 mg/kg and 40 mg/kg of NO-Cbl respectively.","Pharmacokinetics of intravenous nitrosylcobalamin, an antitumor agent, in healthy Beagle dogs: a pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993315/),[pg] / [ml],"2265,",84679,DB00115,Cyanocobalamin
,22993315,peak serum concentrations,"Average peak serum concentrations of 2265, 5523 and 13,866 pg/mL were achieved following single-dose bolus intravenous administration of 10 mg/kg, 20 mg/kg and 40 mg/kg of NO-Cbl respectively.","Pharmacokinetics of intravenous nitrosylcobalamin, an antitumor agent, in healthy Beagle dogs: a pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993315/),[pg] / [ml],5523,84680,DB00115,Cyanocobalamin
,22993315,peak serum concentrations,"Average peak serum concentrations of 2265, 5523 and 13,866 pg/mL were achieved following single-dose bolus intravenous administration of 10 mg/kg, 20 mg/kg and 40 mg/kg of NO-Cbl respectively.","Pharmacokinetics of intravenous nitrosylcobalamin, an antitumor agent, in healthy Beagle dogs: a pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993315/),[pg] / [ml],"13,866",84681,DB00115,Cyanocobalamin
,22993315,area under the curve,"The average area under the curve was 12,697 h × pg/mL, 24,497 h × pg/mL and 44,976 h × pg/mL respectively, with an average elimination half-life of 16.2 h, 13.5 h and 13.1 h respectively.","Pharmacokinetics of intravenous nitrosylcobalamin, an antitumor agent, in healthy Beagle dogs: a pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993315/),[h·pg] / [ml],"12,697",84682,DB00115,Cyanocobalamin
,22993315,area under the curve,"The average area under the curve was 12,697 h × pg/mL, 24,497 h × pg/mL and 44,976 h × pg/mL respectively, with an average elimination half-life of 16.2 h, 13.5 h and 13.1 h respectively.","Pharmacokinetics of intravenous nitrosylcobalamin, an antitumor agent, in healthy Beagle dogs: a pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993315/),[h·pg] / [ml],"24,497",84683,DB00115,Cyanocobalamin
,22993315,area under the curve,"The average area under the curve was 12,697 h × pg/mL, 24,497 h × pg/mL and 44,976 h × pg/mL respectively, with an average elimination half-life of 16.2 h, 13.5 h and 13.1 h respectively.","Pharmacokinetics of intravenous nitrosylcobalamin, an antitumor agent, in healthy Beagle dogs: a pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993315/),[h·pg] / [ml],"44,976",84684,DB00115,Cyanocobalamin
,22993315,elimination half-life,"The average area under the curve was 12,697 h × pg/mL, 24,497 h × pg/mL and 44,976 h × pg/mL respectively, with an average elimination half-life of 16.2 h, 13.5 h and 13.1 h respectively.","Pharmacokinetics of intravenous nitrosylcobalamin, an antitumor agent, in healthy Beagle dogs: a pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993315/),h,16.2,84685,DB00115,Cyanocobalamin
,22993315,elimination half-life,"The average area under the curve was 12,697 h × pg/mL, 24,497 h × pg/mL and 44,976 h × pg/mL respectively, with an average elimination half-life of 16.2 h, 13.5 h and 13.1 h respectively.","Pharmacokinetics of intravenous nitrosylcobalamin, an antitumor agent, in healthy Beagle dogs: a pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993315/),h,13.5,84686,DB00115,Cyanocobalamin
,22993315,elimination half-life,"The average area under the curve was 12,697 h × pg/mL, 24,497 h × pg/mL and 44,976 h × pg/mL respectively, with an average elimination half-life of 16.2 h, 13.5 h and 13.1 h respectively.","Pharmacokinetics of intravenous nitrosylcobalamin, an antitumor agent, in healthy Beagle dogs: a pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993315/),h,13.1,84687,DB00115,Cyanocobalamin
,9489599,maximal plasma cobalamin concentration (Cmax),The maximal plasma cobalamin concentration (Cmax) after nasal administration of 750 microg hydroxocobalamin was 1900 +/- 900 pmol l(-1) (mean +/- s.d.).,Nasal absorption of hydroxocobalamin in healthy elderly adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489599/),[pM] / [l],1900,100125,DB00115,Cyanocobalamin
,9489599,t[max],The maximal plasma cobalamin concentration was reached in 35 +/- 13 min (t[max]).,Nasal absorption of hydroxocobalamin in healthy elderly adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489599/),min,35,100126,DB00115,Cyanocobalamin
,9489599,Cmax,The Cmax after nasal administration of 1500 microg hydroxocobalamin was 3500 +/- 2500 pmol l(-1) with a t(max) of 28 +/- 16 min.,Nasal absorption of hydroxocobalamin in healthy elderly adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489599/),[pM] / [l],3500,100127,DB00115,Cyanocobalamin
,9489599,t(max),The Cmax after nasal administration of 1500 microg hydroxocobalamin was 3500 +/- 2500 pmol l(-1) with a t(max) of 28 +/- 16 min.,Nasal absorption of hydroxocobalamin in healthy elderly adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489599/),min,28,100128,DB00115,Cyanocobalamin
,31946217,bioavailability,"While the bioavailability for the SC route is found to be slightly higher compared to the ID route (99% vs. 96%), the Tmax for both are almost identical.","In-vivo Intradermal Delivery of Co-57 labeled Vitamin B-12, and Subsequent Comparison with Standard Subcutaneous Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31946217/),%,99,119190,DB00115,Cyanocobalamin
,31946217,bioavailability,"While the bioavailability for the SC route is found to be slightly higher compared to the ID route (99% vs. 96%), the Tmax for both are almost identical.","In-vivo Intradermal Delivery of Co-57 labeled Vitamin B-12, and Subsequent Comparison with Standard Subcutaneous Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31946217/),%,96,119191,DB00115,Cyanocobalamin
,17145830,MTD,"The MTD of pemetrexed was 2,400 mg/m(2) (combined with cyclophosphamide, 600 mg/m(2)) with dose-limiting toxicities of grade 4 neutropenia with grade 4 infection and grade 3 diarrhea.",A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145830/),[mg] / [m],"2,400",126316,DB00115,Cyanocobalamin
,14988450,maximum plasma folate response,"The maximum plasma folate response did not differ between the two treatments (mean +/- SEM, 33.4 +/- 3.9 vs.",The short-term bioavailabilities of [6S]-5-methyltetrahydrofolate and folic acid are equivalent in men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14988450/),,33.4,128152,DB00115,Cyanocobalamin
,16940981,MTD/RD,"The MTD/RD were determined to be 1,200/1,000 mg m(-2), respectively.",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,200",151074,DB00115,Cyanocobalamin
,16940981,MTD/RD,"The MTD/RD were determined to be 1,200/1,000 mg m(-2), respectively.",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,000",151075,DB00115,Cyanocobalamin
,16940981,MTD/RD,"The MTD/RD of pemetrexed were determined to be 1,200/1,000 mg m(-2), respectively, that is, a higher RD than without FA/VB(12) (500 mg m(-2)).",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,200",151076,DB00115,Cyanocobalamin
,16940981,MTD/RD,"The MTD/RD of pemetrexed were determined to be 1,200/1,000 mg m(-2), respectively, that is, a higher RD than without FA/VB(12) (500 mg m(-2)).",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,000",151077,DB00115,Cyanocobalamin
,8492341,t1/2 (alpha),"Pharmacokinetic parameters of hydroxocobalamin were best defined in the group who received both antidotes: t1/2 (alpha), 0.52 h; t1/2 (beta), 2.83 h; Vd (beta), 0.24 L/kg; and mean peak serum concentration 753 mcg/mL (560 mumol/L) at 0-50 minutes after completion of infusion.","Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8492341/),h,0.52,164343,DB00115,Cyanocobalamin
,8492341,t1/2 (beta),"Pharmacokinetic parameters of hydroxocobalamin were best defined in the group who received both antidotes: t1/2 (alpha), 0.52 h; t1/2 (beta), 2.83 h; Vd (beta), 0.24 L/kg; and mean peak serum concentration 753 mcg/mL (560 mumol/L) at 0-50 minutes after completion of infusion.","Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8492341/),h,2.83,164344,DB00115,Cyanocobalamin
,8492341,Vd (beta),"Pharmacokinetic parameters of hydroxocobalamin were best defined in the group who received both antidotes: t1/2 (alpha), 0.52 h; t1/2 (beta), 2.83 h; Vd (beta), 0.24 L/kg; and mean peak serum concentration 753 mcg/mL (560 mumol/L) at 0-50 minutes after completion of infusion.","Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8492341/),[l] / [kg],0.24,164345,DB00115,Cyanocobalamin
,8492341,peak serum concentration,"Pharmacokinetic parameters of hydroxocobalamin were best defined in the group who received both antidotes: t1/2 (alpha), 0.52 h; t1/2 (beta), 2.83 h; Vd (beta), 0.24 L/kg; and mean peak serum concentration 753 mcg/mL (560 mumol/L) at 0-50 minutes after completion of infusion.","Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8492341/),[mcg] / [ml],753,164346,DB00115,Cyanocobalamin
,2376694,t1/2,"While mean t1/2 measurements for the initial distribution phase were similar for HO-Cbl and CN-Cbl, the secondary excretion phase was more prolonged for HO-Cbl than for CN-Cbl (t1/2, 94.75 minutes vs 62.64 minutes, respectively).",Studies of cobalamin as a vehicle for the renal excretion of cyanide anion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376694/),min,94.75,171493,DB00115,Cyanocobalamin
,2376694,t1/2,"While mean t1/2 measurements for the initial distribution phase were similar for HO-Cbl and CN-Cbl, the secondary excretion phase was more prolonged for HO-Cbl than for CN-Cbl (t1/2, 94.75 minutes vs 62.64 minutes, respectively).",Studies of cobalamin as a vehicle for the renal excretion of cyanide anion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376694/),min,62.64,171494,DB00115,Cyanocobalamin
,28400198,percentages of moisture content,"The percentages of moisture content of the optimized formulation were 3.2 ± 0.95, whereas the percentage drug released was 98.59 ± 1.41% at the end of 40 min.",Vitamin B12-Loaded Buccoadhesive Films as a Noninvasive Supplement in Vitamin B12 Deficiency: In Vitro Evaluation and In Vivo Comparative Study With Intramuscular Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28400198/),,3.2,177226,DB00115,Cyanocobalamin
,28400198,percentage drug released,"The percentages of moisture content of the optimized formulation were 3.2 ± 0.95, whereas the percentage drug released was 98.59 ± 1.41% at the end of 40 min.",Vitamin B12-Loaded Buccoadhesive Films as a Noninvasive Supplement in Vitamin B12 Deficiency: In Vitro Evaluation and In Vivo Comparative Study With Intramuscular Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28400198/),%,98.59,177227,DB00115,Cyanocobalamin
,8354595,rate of relative bioavailability,"The mean index for the rate of relative bioavailability was, in fact, estimated to be 106.3 +/- 12.4%.",Pharmacokinetic study of the relative bioavailability and bioequivalence after oral intensive or repeated short term treatment with two polyamino acid formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8354595/),%,106.3,185313,DB00115,Cyanocobalamin
,23262165,absolute bioavailability,Thiolated formulations provided an absolute bioavailability of 0.89%.,Development and in vivo evaluation of an oral vitamin B12 delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23262165/),%,0.89,187920,DB00115,Cyanocobalamin
,1190217,Excretion,"Excretion, a measure of absorption, was between 2 percent and 66 percent greater with the liquid form.",Comparison of the bioavailability of cyanocobalamin from capsule and liquid dosage forms. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190217/),%,2,196434,DB00115,Cyanocobalamin
,1190217,Excretion,"Excretion, a measure of absorption, was between 2 percent and 66 percent greater with the liquid form.",Comparison of the bioavailability of cyanocobalamin from capsule and liquid dosage forms. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190217/),%,66,196435,DB00115,Cyanocobalamin
,10571286,terminal half-life,The terminal half-life of the drug following I.V. administration in four dogs was found to be 16.4+/-2.4 hrs.,In vitro-in vivo evaluation of a controlled release buccal bioadhesive device for oral drug delivery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10571286/),h,16.4,206010,DB00115,Cyanocobalamin
,10571286,Cmax,"Following immediate release oral capsule administration of the drug Cmax, tmax and bioavailability were 2333+/-1469 ng/L, 2.5+/-1.0 hrs and 14.1+/-7.9%, respectively.",In vitro-in vivo evaluation of a controlled release buccal bioadhesive device for oral drug delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10571286/),[ng] / [l],2333,206011,DB00115,Cyanocobalamin
,10571286,tmax,"Following immediate release oral capsule administration of the drug Cmax, tmax and bioavailability were 2333+/-1469 ng/L, 2.5+/-1.0 hrs and 14.1+/-7.9%, respectively.",In vitro-in vivo evaluation of a controlled release buccal bioadhesive device for oral drug delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10571286/),h,2.5,206012,DB00115,Cyanocobalamin
,10571286,bioavailability,"Following immediate release oral capsule administration of the drug Cmax, tmax and bioavailability were 2333+/-1469 ng/L, 2.5+/-1.0 hrs and 14.1+/-7.9%, respectively.",In vitro-in vivo evaluation of a controlled release buccal bioadhesive device for oral drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10571286/),%,14.1,206013,DB00115,Cyanocobalamin
,10571286,Cmax,"Following buccal bioadhesive device administration of the drug Cmax, t(max) and bioavailability were 4154+/-1096 ng/L, 11+/-1.2 hrs and 35.8+/-4.1%, respectively.",In vitro-in vivo evaluation of a controlled release buccal bioadhesive device for oral drug delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10571286/),[ng] / [l],4154,206014,DB00115,Cyanocobalamin
,10571286,t(max),"Following buccal bioadhesive device administration of the drug Cmax, t(max) and bioavailability were 4154+/-1096 ng/L, 11+/-1.2 hrs and 35.8+/-4.1%, respectively.",In vitro-in vivo evaluation of a controlled release buccal bioadhesive device for oral drug delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10571286/),h,11,206015,DB00115,Cyanocobalamin
,10571286,bioavailability,"Following buccal bioadhesive device administration of the drug Cmax, t(max) and bioavailability were 4154+/-1096 ng/L, 11+/-1.2 hrs and 35.8+/-4.1%, respectively.",In vitro-in vivo evaluation of a controlled release buccal bioadhesive device for oral drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10571286/),%,35.8,206016,DB00115,Cyanocobalamin
,27416488,Papp,The apparent permeability of Hdrx was Papp = 34.9 ± 4.6 × 10-6 cm/s in the presence of 3 mg/mL (HB12 B) compared to the control Papp = 6.2 ± 0.7 × 10-6 cm/s.,Hibiscus sabdariffa increases hydroxocobalamin oral bioavailability and clinical efficacy in vitamin B12 deficiency with neurological symptoms. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416488/),[cm] / [s],34.9,213668,DB00115,Cyanocobalamin
,27416488,Papp,The apparent permeability of Hdrx was Papp = 34.9 ± 4.6 × 10-6 cm/s in the presence of 3 mg/mL (HB12 B) compared to the control Papp = 6.2 ± 0.7 × 10-6 cm/s.,Hibiscus sabdariffa increases hydroxocobalamin oral bioavailability and clinical efficacy in vitamin B12 deficiency with neurological symptoms. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416488/),[cm] / [s],6.2,213669,DB00115,Cyanocobalamin
,27416488,Gt,"(ii) Total transepithelial electrical conductance (Gt ) increased in dose-dependent manner with HB12 , Gt = 161.5 ± 10.8 mS/cm² with HB12 B (Hdrx 1 mg + HS 3 mg) compared to the control Hdrx, Gt = 28.7 ± 4.0 mS/cm².",Hibiscus sabdariffa increases hydroxocobalamin oral bioavailability and clinical efficacy in vitamin B12 deficiency with neurological symptoms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416488/),[ms] / [cm²],161.5,213670,DB00115,Cyanocobalamin
,27416488,Gt,"(ii) Total transepithelial electrical conductance (Gt ) increased in dose-dependent manner with HB12 , Gt = 161.5 ± 10.8 mS/cm² with HB12 B (Hdrx 1 mg + HS 3 mg) compared to the control Hdrx, Gt = 28.7 ± 4.0 mS/cm².",Hibiscus sabdariffa increases hydroxocobalamin oral bioavailability and clinical efficacy in vitamin B12 deficiency with neurological symptoms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416488/),[ms] / [cm²],28.7,213671,DB00115,Cyanocobalamin
,15730428,half-life,"3. The half-life of cyanocobalamin ranged from approximately 20 to 50 min, clearance ranged from 4.5 to 9 mL/min and the volume of distribution at steady state ranged from 140 to 470 mL.",Pharmacokinetics of high doses of cyanocobalamin administered by intravenous injection for 26 weeks in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730428/),min,20 to 50,213856,DB00115,Cyanocobalamin
,15730428,clearance,"3. The half-life of cyanocobalamin ranged from approximately 20 to 50 min, clearance ranged from 4.5 to 9 mL/min and the volume of distribution at steady state ranged from 140 to 470 mL.",Pharmacokinetics of high doses of cyanocobalamin administered by intravenous injection for 26 weeks in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730428/),[ml] / [min],4.5 to 9,213857,DB00115,Cyanocobalamin
,15730428,volume of distribution at steady state,"3. The half-life of cyanocobalamin ranged from approximately 20 to 50 min, clearance ranged from 4.5 to 9 mL/min and the volume of distribution at steady state ranged from 140 to 470 mL.",Pharmacokinetics of high doses of cyanocobalamin administered by intravenous injection for 26 weeks in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730428/),ml,140 to 470,213858,DB00115,Cyanocobalamin
,2555466,biologic half-life,"Also, regardless of the presence of neomycin, the biologic half-life of injected [57Co]vitamin B-12 was 58 d for rats fed the fiber-free diets and only 38 d for rats fed 5% pectin diets.",Neomycin has no persistent sparing effect on vitamin B-12 status in pectin-fed rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2555466/),d,58,232573,DB00115,Cyanocobalamin
,2555466,biologic half-life,"Also, regardless of the presence of neomycin, the biologic half-life of injected [57Co]vitamin B-12 was 58 d for rats fed the fiber-free diets and only 38 d for rats fed 5% pectin diets.",Neomycin has no persistent sparing effect on vitamin B-12 status in pectin-fed rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2555466/),d,38,232574,DB00115,Cyanocobalamin
,21722960,absolute bioavailability,"The oral cyanocobalamin formulation containing SNAC had greater mean absolute bioavailability than the commercial oral formulation (5.09% vs 2.16%, respectively), calculated on AUC(0-last) values uncorrected for baseline, weight, or body mass index.","Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21722960/),%,5.09,243443,DB00115,Cyanocobalamin
,21722960,absolute bioavailability,"The oral cyanocobalamin formulation containing SNAC had greater mean absolute bioavailability than the commercial oral formulation (5.09% vs 2.16%, respectively), calculated on AUC(0-last) values uncorrected for baseline, weight, or body mass index.","Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21722960/),%,2.16,243444,DB00115,Cyanocobalamin
,21722960,T(max),"It also had a reduced T(max) compared with the commercial formulation (0.5 hours vs 6.83 hours, respectively).","Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21722960/),h,0.5,243445,DB00115,Cyanocobalamin
,21722960,T(max),"It also had a reduced T(max) compared with the commercial formulation (0.5 hours vs 6.83 hours, respectively).","Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21722960/),h,6.83,243446,DB00115,Cyanocobalamin
,21722960,K(e),The K(e) was similar between treatments (0.028 1/h vs 0.025 1/h).,"Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21722960/),[1] / [h],0.028,243447,DB00115,Cyanocobalamin
,21722960,K(e),The K(e) was similar between treatments (0.028 1/h vs 0.025 1/h).,"Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21722960/),[1] / [h],0.025,243448,DB00115,Cyanocobalamin
,21841501,response rate,"The response rate was 10% (95% confidence interval: 1-20%), including two patients with complete response (26+ and 32+ months) and two with partial response.","Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21841501/),%,10,243484,DB00115,Cyanocobalamin
,31389254,time to euthanasia,"KCN 0.08 mmol/kg was survived by 4/4 animals with moderate cardiovascular effects, while the 0.12 mmol/kg dose was lethal in 4/4 animals, with a mean time to euthanasia of 28.3 (SEM: 13.9) min.",Modest and variable efficacy of pre-exposure hydroxocobalamin and dicobalt edetate in a porcine model of acute cyanide salt poisoning. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31389254/),min,28.3,264790,DB00115,Cyanocobalamin
,8699553,Distribution half-life,Distribution half-life is on the order of 1.86 +/- 0.34 h and the elimination half-life 26.2 +/- 2.7 h.,Pharmacokinetics of hydroxocobalamin in smoke inhalation victims. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699553/),h,1.86,270887,DB00115,Cyanocobalamin
,8699553,elimination half-life,Distribution half-life is on the order of 1.86 +/- 0.34 h and the elimination half-life 26.2 +/- 2.7 h.,Pharmacokinetics of hydroxocobalamin in smoke inhalation victims. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699553/),h,26.2,270888,DB00115,Cyanocobalamin
,8699553,apparent volume of distribution,The apparent volume of distribution is 0.45 +/- 0.03 L/kg.,Pharmacokinetics of hydroxocobalamin in smoke inhalation victims. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699553/),[l] / [kg],0.45,270889,DB00115,Cyanocobalamin
,8699553,Renal,"Renal and total body clearance are 0.31 +/- 0.06 and 0.83 +/- 0.07 L/h, respectively.",Pharmacokinetics of hydroxocobalamin in smoke inhalation victims. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699553/),[l] / [h],0.31,270890,DB00115,Cyanocobalamin
,8699553,total body clearance,"Renal and total body clearance are 0.31 +/- 0.06 and 0.83 +/- 0.07 L/h, respectively.",Pharmacokinetics of hydroxocobalamin in smoke inhalation victims. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699553/),[l] / [h],0.83,270891,DB00115,Cyanocobalamin
,11041441,absorption,"There was 30% greater B12 absorption for Stuartnatal Plus (371 +/- 56 vs. 285 +/- 34 pmol) and 33% for Materna (315 +/- 34 vs. 236 +/- 4 pmol, p < or = 0.05).",Vitamin B12 and folate bioavailability from two prenatal multivitamin/multimineral supplements. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041441/),pM,371,272198,DB00115,Cyanocobalamin
,11041441,absorption,"There was 30% greater B12 absorption for Stuartnatal Plus (371 +/- 56 vs. 285 +/- 34 pmol) and 33% for Materna (315 +/- 34 vs. 236 +/- 4 pmol, p < or = 0.05).",Vitamin B12 and folate bioavailability from two prenatal multivitamin/multimineral supplements. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041441/),pM,285,272199,DB00115,Cyanocobalamin
,11041441,absorption,"There was 30% greater B12 absorption for Stuartnatal Plus (371 +/- 56 vs. 285 +/- 34 pmol) and 33% for Materna (315 +/- 34 vs. 236 +/- 4 pmol, p < or = 0.05).",Vitamin B12 and folate bioavailability from two prenatal multivitamin/multimineral supplements. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041441/),pM,315,272200,DB00115,Cyanocobalamin
,11041441,absorption,"There was 30% greater B12 absorption for Stuartnatal Plus (371 +/- 56 vs. 285 +/- 34 pmol) and 33% for Materna (315 +/- 34 vs. 236 +/- 4 pmol, p < or = 0.05).",Vitamin B12 and folate bioavailability from two prenatal multivitamin/multimineral supplements. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041441/),pM,236,272201,DB00115,Cyanocobalamin
,11041441,absorption,"Similarly, there was 117% greater folate absorption fasting for Stuartnatal Plus (163 +/- 15 vs. 75 +/- 15 nmol, p < or = 0.001) and 57% greater absorption for Materna (207 +/- 21 vs. 132 +/- 13 nmol, p < or = 0.01).",Vitamin B12 and folate bioavailability from two prenatal multivitamin/multimineral supplements. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041441/),nM,163,272202,DB00115,Cyanocobalamin
,11041441,absorption,"Similarly, there was 117% greater folate absorption fasting for Stuartnatal Plus (163 +/- 15 vs. 75 +/- 15 nmol, p < or = 0.001) and 57% greater absorption for Materna (207 +/- 21 vs. 132 +/- 13 nmol, p < or = 0.01).",Vitamin B12 and folate bioavailability from two prenatal multivitamin/multimineral supplements. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041441/),nM,75,272203,DB00115,Cyanocobalamin
,11041441,absorption,"Similarly, there was 117% greater folate absorption fasting for Stuartnatal Plus (163 +/- 15 vs. 75 +/- 15 nmol, p < or = 0.001) and 57% greater absorption for Materna (207 +/- 21 vs. 132 +/- 13 nmol, p < or = 0.01).",Vitamin B12 and folate bioavailability from two prenatal multivitamin/multimineral supplements. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041441/),nM,207,272204,DB00115,Cyanocobalamin
,11041441,absorption,"Similarly, there was 117% greater folate absorption fasting for Stuartnatal Plus (163 +/- 15 vs. 75 +/- 15 nmol, p < or = 0.001) and 57% greater absorption for Materna (207 +/- 21 vs. 132 +/- 13 nmol, p < or = 0.01).",Vitamin B12 and folate bioavailability from two prenatal multivitamin/multimineral supplements. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041441/),nM,132,272205,DB00115,Cyanocobalamin
